[Secondary osteoporosis. Chronic obstructive pulmonary disease:COPD.]

Area of Science:

• Pulmonary Medicine
• Endocrinology
• Bone Biology

Background:

• Chronic obstructive pulmonary disease (COPD) is an inflammatory lung condition primarily caused by smoking.
• COPD is a systemic disease with extra-pulmonary complications, including osteoporosis, ischemic heart disease, and sarcopenia.
• Vertebral fractures are prevalent in COPD patients, even in early stages, indicating significant bone fragility.

Purpose of the Study:

• To elucidate the pathophysiology of bone fragility in COPD-associated osteoporosis.
• To identify key risk factors contributing to bone density loss and deterioration in COPD.
• To emphasize the importance of managing osteoporosis in COPD patients.

Main Methods:

• Review of existing literature on COPD, osteoporosis, and related risk factors.
• Analysis of the interplay between systemic inflammation, glucocorticoid therapy, and vitamin D status in COPD.
• Examination of the impact on bone mineral density and bone quality.

Main Results:

• COPD-associated osteoporosis is multifactorial, driven by systemic inflammation, glucocorticoid use, and vitamin D insufficiency/deficiency.
• These factors contribute to decreased bone mineral density and impaired bone quality, increasing fracture risk.
• The pathophysiology linking COPD to bone fragility is complex and requires further investigation.

Conclusions:

• Vitamin D repletion is essential for managing bone health in COPD patients.
• Timely intervention with anti-osteoporotic medications is critical for preventing fractures.
• Integrated management strategies addressing both pulmonary and bone health are necessary for improving patient outcomes.